This event is now closed, information is displayed here for information only.
The 2017 ‘Frontiers of Oncology: Haematology’ meeting will be announced in January 2017
but you can pre-register HERE to be advised when the programme is released

 

A one day meeting held on
Friday 1st July 2016
The Royal College of Physicians, London, UK


Chairs

Tariq Enver
Professor Tariq Enver
Director
UCL Cancer Institute
Adele FieldingProfessor Adele Fielding
Professor of Haematology
UCL Cancer Institute

From 08.00 Registration & Coffee
09.00 Welcome to the event / setting the scene: the Chairmen
SESSION 1: BMT
09.05 Introduction from session Chair: Professor Tariq Enver
09.10 Targeted radiotherapy – Radio-labelled anti-CD66 antibodies for allograft conditioning
Dr Kim Orchard
Senior Lecturer, University of Southampton
09.30 The influence of reduced intensity conditioning and the future of allograft conditioning regimens
Professor Stephen Mackinnon
Professor of Haematology, UCL Cancer Institute, London, UK
09.50 Progress towards separating GVHD from GVL
Professor Ronjon Chakraverty
Professor of Cellular Immunotherapy, UCL Cancer Institute, London, UK
10.10 Q&A
All
10.25 Break
SESSION 2: Lymphoma
10.55 Introduction from session Chair: Professor David Linch
11.00 Immune checkpoint therapy for lymphomas (inc. Q&A)
Professor Karl Peggs
Professor of Stem Cell Transplantation & Immunotherapy, UCL Cancer Institute, London, UK
11.25 Recent genetic insights into lymphoma (inc. Q&A)
Professor Jude Fitzgibbon
Professor of Personalised Cancer Medicine, Bart’s Cancer Institute, London, UK
11.50 State of the art therapy for rare lymphoma subtypes (inc. Q&A)
Dr Kate Cwynarski
Consultant Haematologist UCLH, Honorary Clinical Senior Lecturer UCL Cancer Institute, London, UK
12.15 Summary
12.20 Lunch
SESSION 3: ALL / AML
13.10 Introduction from session Chair: Adele Fielding
13.15 T ALL – A summary of the genetic landscape and its impact on therapeutic outcome
Dr Marc Mansour
Professorial Research Fellow, UCL Cancer Institute, London, UK
13.35 Novel approaches to treating B-ALL
Professor Adele Fielding
Professor of Haematology, UCL Cancer Institute, London, UK
13.55 Challenges associated with the molecular heterogeneity in AML
Professor Rosemary Gale
Professor of Haematology, UCL Cancer Institute, London, UK
14.15 Q&A
14.30 Break
SESSION 4: Myeloma
15.00 Introduction from session Chair: Professor Kwee Yong
15.05 Bromodomain inhibitors explained and their potential utility in the therapy of multiple myeloma
Professor Anastasios Karadimitris
Professor of Haematology, Imperial College London, UK
15.30 Early clinical development of new treatments in myeloma
Dr Rakesh Popat
Consultant Haematologist at UCLH, Honorary Clinical Senior Lecturer at the UCL Cancer Institute, London, UK
15.55 A redefinition of myeloma
Dr Jenny Bird
Consultant Haematologist, University Hospitals Bristol, UK
16.30 Summary & Close

This meeting is organised by:

New UCL Logo2 800

ATL-new-logo-July-2015-800px

and endorsed and supported by:

The Lancet Haematology
The Lancet Oncology
The Lancet

Lymphoma Association


The Frontiers of Oncology 2018 meetings are supported by grants from the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.